The challenge to further improvements in survival of patients with T-ALL: Current treatments and new insights from disease pathogenesis

Survival rates for children and adult patients with T-cell acute lymphoblastic leukemia (T-ALL) have improved during the past decade due to optimization of frontline multiagent chemotherapy regimens. The outcome for relapsed T-ALL after initial intensive chemotherapy is frequently fatal, however, be...

Full description

Saved in:
Bibliographic Details
Published inSeminars in hematology Vol. 57; no. 3; p. 149
Main Author O'Dwyer, Kristen M
Format Journal Article
LanguageEnglish
Published United States 01.07.2020
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:Survival rates for children and adult patients with T-cell acute lymphoblastic leukemia (T-ALL) have improved during the past decade due to optimization of frontline multiagent chemotherapy regimens. The outcome for relapsed T-ALL after initial intensive chemotherapy is frequently fatal, however, because no effective salvage regimens have been developed. Immunotherapy and small molecule inhibitors are beginning to be tested in T-ALL and have the potential to advance the treatment, especially the frontline regimen by eradicating minimal residual disease thus inducing more durable remissions. In this paper, I review the current chemotherapy regimens for adult patients with T-ALL and summarize the novel immunotherapies and small molecule inhibitors that are currently in early phase clinical trials.
ISSN:1532-8686
DOI:10.1053/j.seminhematol.2020.11.004